Bispecific antibody treatment of multiple myeloma: latest updates from the 2022 ASH annual meeting.

ABSTRACT:

Background

Effective novel therapies for multiple myeloma (MM) patients who are unresponsive to conventional treatments (triple-class refractory) are an urgent need. Bispecific antibodies (BsAbs) offer a promising new approach to stimulate T cells and induce tumor cell death by targeting molecules on the surface of malignant plasma cells and CD3 on the surface of T cells.

Objectives

Addressing the issue of improving the prognosis of triple-class refractory MM patients has become a significant clinical challenge.

Design

This is a brief report.

Methods

This article summarizes the latest updates of BsAbs treatment of MM from the 2022 ASH annual meeting.

Results

BsAbs that target B-cell maturation antigen and G protein-coupled receptor family C group 5 membe

SUBMITTER: Yin X 

PROVIDER: S-EPMC10657518 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature